摘要
目的:探讨达沙替尼单独及联合卡铂应用对人卵巢癌OVCAR3、HO8910细胞生长的影响及可能的分子机制。方法:MTT法检测达沙替尼联合卡铂对人卵巢癌OVCAR3、HO8910细胞增殖的抑制率;采用流式细胞仪检测达沙替尼联合卡铂处理OVCAR3、HO8910细胞的凋亡率。Western blot检测EphA2蛋白表达变化。结果:达沙替尼单独及联合卡铂应用均可显著抑制人卵巢癌OVCAR3、HO8910细胞的增殖,其作用呈现剂量依赖性,且两药联合作用时抑制率显著增高(P<0.05),显示两药有协同作用;流式细胞术检测显示达沙替尼能使卵巢癌OVCAR3、HO8910细胞凋亡率随用药浓度增加而增加。结论:体外人卵巢癌OVCAR3、HO8 910细胞对达沙替尼联合卡铂具有药物敏感性;EphA2蛋白的表达可能是达沙替尼联合卡铂诱导卵巢癌细胞的机制。
Objective：To explore the effect of dasatinib combined with carboplatin on the growth of human ovarian cancer OVCAR3 and HO8910 cells and the possible molecular mechanism. Methods：MTT assay was used to detect the inhibitory rate of dasatinib combined with carboplatin on the proliferation of human ovarian cancer OVCAR3 and HO8910 cells;flow cytometry was used to detect the apoptosis rates of human ovarian cancer OVCAR3 and HO8910 cells after treated with dasatinib combined with carboplatin.The change of EphA2 protein expression was detected by Western blot. Results：Dasatinib alone or dasatinib combined with carboplatin both could inhibit the proliferation of human ovarian cancer OVCAR3 and HO8910 cells significantly,showing a dose-dependent manner,and the inhibitory rate of dasatinib combined with carboplatin increased significantly（P0.05）,showing a synergistic effect;flow cytometry showed that the apoptosis rates of human ovarian cancer OVCAR3 and HO8910 cells after treated with dasatinib increased with the increase of drug concentration. Conclusion：Human ovarian cancer OVCAR3 and HO8910 cells are sensitive to dasatinib combined with carboplatin;the expression of EphA2 protein may be one of the mechanisms of ovarian cancer cells induced by dasatinib combined with carboplatin.
出处
《中国妇幼保健》
CAS
北大核心
2011年第24期3784-3787,共4页
Maternal and Child Health Care of China
基金
辽宁省自然科学基金项目〔20092102〕
辽宁省教育厅基金项目〔20060961〕
